{"url_path":"/sec/celuw/8-k/2026-06-03/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1752828/0001493152-26-027132-index.html","accession_number":"0001493152-26-027132","cik":"0001752828","ticker":"CELU","issuer_name":"Celularity Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1752828/0001493152-26-027132-index.html","primary_entity_key":"0001752828","primary_entity_name":"Celularity Inc"},"word_count":94,"has_tables":true,"body_markdown":"**Item\n9.01. Financial Statements and Exhibits.**\n\n \n\n(d)\nExhibits\n\n \n\n99.1\n \n[Press release issued by Celularity Inc. on June 3, 2026.](ex99-1.htm)\n\n99.2\n \n[Letter to Shareholders from Robert J. Hariri, MD, PhD, Chairman and CEO, dated June 3, 2023](ex99-2.htm)\n\n104\n \nCover\nPage Interactive Data File (formatted as Inline XBRL)\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**CELULARITY\nINC**.\n\nDated:\nJune 3, 2026\n \n\n \nBy:\n\n*/s/\nJohn Sprague*\n\n \nName:\nJohn\nSprague\n\n \nTitle:\nChief\nFinancial Officer"}